Etanercept protects rat cardiomyocytes against hypertrophy by regulating inflammatory cytokines secretion and cell apoptosis

Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas
Q LiB Liu

Abstract

We aimed to investigate the effect of etanercept, a tumor necrosis factor-α (TNF-α) inhibitor, on rat cardiomyocyte hypertrophy and its underlying mechanism. Primary neonatal rat cardiomyocytes were isolated from Sprague-Dawley rats. The model of rat cardiomyocyte hypertrophy was induced by endothelin, and then treated with different concentrations of etanercept (1, 10, and 50 μM). After treatment, cell counts, viability and cell apoptosis were evaluated. The mRNA levels of myocardial hypertrophy marker genes, including atrial natriuretic factor (ANF), matrix metalloproteinase (MMP)-9 and MMP-13, were detected by qRT-PCR, and the expressions of apoptosis-related proteins (Bcl-2 and Bax) were measured by western blotting. The protein levels of transforming growth factor-β1 (TGF-β1), interleukin (IL)-1β, IL-6, leukemia inhibitory factor (LIF) and cardiotrophin-1 (CT-1) were determined using enzyme linked immunosorbent assay (ELISA) kits. In the present study, TNF-α level in cardiomyocytes with hypertrophy was significantly enhanced (P<0.05). Compared to the model group, cell number and viability were significantly increased and ratio of apoptotic cells was reduced by etanercept (P<0.05, P<0.01, or P<0.001). In addition, etanercep...Continue Reading

References

Apr 6, 1999·Trends in Cardiovascular Medicine·G W Dorn, J H Brown
Oct 26, 1999·Cardiovascular Research·G F Tomaselli, E Marbán
Oct 30, 2001·Pflügers Archiv : European journal of physiology·M PattenC Long
Dec 5, 2003·Journal of Molecular and Cellular Cardiology·Qiangrong Liang, Jeffery D Molkentin
Jul 28, 2004·Cardiovascular Research·Giulio SelvetellaGiuseppe Lembo
Aug 18, 2004·Biochemical and Biophysical Research Communications·Doubun HayashiIssei Komuro
Mar 15, 2005·The Journal of Clinical Investigation·Gerald W Dorn, Thomas Force
Jun 21, 2005·Pharmacology & Therapeutics·Denise Hilfiker-KleinerHelmut Drexler
Jul 25, 2006·Journal of Molecular and Cellular Cardiology·Raúl A DulceMaría C Camilión de Hurtado
Oct 3, 2006·Journal of the American Academy of Dermatology·Rama MalaviyaAlice B Gottlieb
Jul 23, 2008·International Journal of Medical Sciences·Walter FriesEmanuela Mazzon
Jul 17, 2010·The British Journal of Dermatology·G AvramidisA Tosca
Jan 22, 2011·Circulation Research·Petra Eder, Jeffery D Molkentin
Mar 8, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Christopher KnightRobert Boggs
Mar 6, 2013·The Journal of Pathology·John P WatersJohn R Bradley
Nov 29, 2013·Annals of the Rheumatic Diseases·M NeoviusUNKNOWN ARTIS Study Group
Oct 11, 2014·Expert Opinion on Drug Metabolism & Toxicology·Giuseppe MurdacaFrancesco Puppo
Jun 6, 2016·Journal of Molecular and Cellular Cardiology·Ippei Shimizu, Tohru Minamino
Feb 20, 2017·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Jing LiangYu Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
ELISA
enzyme linked immunosorbent assay

Software Mentioned

SPSS
Image

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.